MGCD0103 facts - Freebase.com

Facts from the Community

From the BioVenturist base

Indication or disease:

Disease	Phase of development	Notes
Pancreatic cancer	Phase II Clinical Trial
Hodgkin's lymphoma	Phase II Clinical Trial
Acute myeloid leukemia	Phase II Clinical Trial
Solid Tumors	Phase I Clinical Trial
Lymphoma	Phase II Clinical Trial
Myelodysplastic syndrome	Phase II Clinical Trial	With Vidaza

View entire collection »

Developed by:

Celgene

Stage of development:

In development

top ↑

We can tell you that MGCD0103 is a…

…Drug
…Medical Treatment

If you know more about MGCD0103, you can add more facts here »

Similar topics in Freebase

Tezosentan

Tezosentan is a non-selective ETA and ETB receptor antagonist. It acts as a vasodilator and was designed as a therapy for patients with acute heart failure. Recent studies have shown however, that tezosentan does not improve dyspnea or reduce the risk of fatal or nonfatal cardiovascular events.
Pomalidomide
CC-11050
CC-10015
CEL_JNK 930
CC-11006
CEL_p38
Apremilast
CEL_ACE-001
AMRUBICIN

These people have edited this topic:

jame0taylor
- Member Since: May 20, 2008
- Contributions: 16,115 Facts

Edit this topic

Last edited Jan 3, 2009 See all topic history »

Edit and Show details

Add or delete facts, download data in JSON or RDF formats, and explore topic metadata.

What is Freebase?

Freebase is a huge collection of facts, built by people like you. Freebase connects facts in ways other sites can't, giving you new ways to explore millions of subjects.
You can help improve it!

Flag this Topic

Why do you want to flag this topic?

Freebase data is free for use under the CC-BY license.

Learn more about Freebase licensing and attribution